AbbVie, BMS in Tumor Clinical Research PactBy
AbbVie and Bristol-Myers Squibb (BMS) have entered into a clinical trial collaboration to evaluate the combination of AbbVie’s investigational antibody drug conjugate (ADC), ABBV-399 (telisotuzumab vedotin), and BMS’s immunotherapy, Opdivo (nivolumab), in c-Met (a receptor tyrosine kinase) overexpressing non-small cell lung cancer (NSCLC).
A Phase Ib clinical study is underway that includes evaluating the potential of combining Opdivo, which is designed to alleviate immune suppression, with ABBV-399 to explore the tolerability and potential efficacy of the combination in subjects with advanced c-Met overexpressing NSCLC who failed one prior line of chemotherapy.
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to harness the body’s own immune system to help restore anti-tumor immune response. ABBV-399 is an anti-c-Met ADC that targets both MET-amplified and c-Met-overexpressing tumors. It is currently being investigated to treat advanced solid tumors.
Opdivo had 2016 sales of $3.77 billion. In the US, Opdivo is indicated for treating BRAF V600 mutation-positive unresectable or metastatic melanoma and BRAF V600 wild-type unresectable or metastatic melanoma as a single agent; unresectable or metastatic melanoma in combination with Yervoy (ipilimumab); metastatic non-small cell lung cancer; advanced renal cell carcinoma; classical Hodgkin lymphoma; recurrent or metastatic squamous cell carcinoma of the head and neck; and locally advanced or metastatic urothelial carcinoma.
Source: AbbVie and Bristol-Myers Squibb